NGM Biopharmaceuticals $125 million follow-on offering
We advised the joint book-running managers on the public equity offering

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $125 million public offering of 4,629,630 shares of common stock by NGM Biopharmaceuticals, Inc. The common stock is listed on the Nasdaq Global Select Market under the symbol “NGM.”

Headquartered in South San Francisco, California, NGM is a biopharmaceutical company focused on discovering and developing novel therapeutics based on scientific understanding of key biological pathways underlying liver and metabolic diseases, retinal diseases and cancer.

The Davis Polk corporate team included partner Stephen Salmon and associates Blake Anderson and Ganiatu Afolabi. Partner David R. Bauer and associate Jay Frankel provided intellectual property advice. The tax team included partner Mario J. Verdolini and associate Rebecca A. Rosen. Counsel Marcie A. Goldstein provided FINRA advice. Associate Sijia Cai provided 1940 Act advice. Members of the Davis Polk team are based in the Northern California and New York offices.